Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Butenafine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.94 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.94 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.94 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.94 |
| ▸ | HTR2A | P28223 | 2/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butenafine SCHEMBL29354083 | 0.97 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL65526 | 0.97 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL20456391 | 0.97 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL676912 | 0.96 | LMNA (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL29459249 | 0.96 | LMNA (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL262301 | 0.96 | LMNA (0.97) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL500751 | 0.90 | CYP2D6 (0.85) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| SCHEMBL9695182 | 0.86 | CYP2D6 (0.80) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| SCHEMBL9312678 | 0.85 | CYP2D6 (0.78) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL9314916 | 0.84 | LMNA (0.76) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| CN-118924715-B | Application of butenafine in resisting mycobacterium abscessus infection | 首都医科大学附属北京胸科医院 | 2025-03-21 | — | — | CN | disclosed |
| CN-118924715-A | Application of butenafine in resisting mycobacterium abscessus infection | 首都医科大学附属北京胸科医院 | 2024-11-12 | — | — | CN | disclosed |
| CN-118873519-A | Application of naftifine in resisting accidental mycobacterial infection | 首都医科大学附属北京胸科医院 | 2024-11-01 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | UNITED STATES GOVERNMENT | 2003-02-13 | — | — | US | disclosed |
| US-6403576-B1 | CHOLESTEROL SYNTHESIS INHIBITOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SLC6A2 804/4885ACHE 281/4885SLC6A3 1960/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | SLC6A2 4136/4885ACHE 3728/4885SLC6A3 4775/4885 |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | PIGO, CAT, ERG28 | SLC6A2 1974/4885ACHE 2119/4885SLC6A3 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.